Founder directory

Non-dilutive funding: SBIR, STTR and the R&D credit

Money that does not cost equity. Where SBIR and STTR stand after their 2025–2026 lapse and reauthorization, and how startups use the R&D tax credit against payroll taxes.

3 min readCash Capital

The short answer

The two largest sources of non-dilutive money for US technology startups are federal SBIR and STTR awards and the federal R&D tax credit. SBIR and STTR were reauthorized on 13 April 2026, through 30 September 2031, after a six-month lapse. Qualified small businesses can apply up to $500,000 a year of R&D credit against payroll taxes.

SBIR and STTR

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs fund research and development at small US businesses through participating federal agencies, together roughly $4 billion a year. STTR requires a partnership with a research institution such as a university.

MilestoneDate
Authorization expired; new awards and solicitations stopped30 September 2025
Reauthorization signed (Small Business Innovation and Economic Security Act, P.L. 119-83)13 April 2026
New authorization runs through30 September 2031

The law also lets agencies carry unspent fiscal year 2026 SBIR and STTR funds into fiscal year 2027, adds a new post-Phase II "Strategic Breakthrough" award category, and tightens foreign-risk reviews. Agencies restarted solicitations at different speeds after reauthorization, so check each agency's own SBIR page for open topics and current award sizes.

How the phases work

  • Phase I: a feasibility award. Amounts and durations vary by agency.
  • Phase II: a larger award to develop the technology, usually for Phase I winners.
  • Phase III: commercialization, funded by private capital or non-SBIR government contracts.

The R&D tax credit and the payroll offset

The federal research credit (Internal Revenue Code § 41) rewards qualified research spending. A startup with no income tax to offset can still benefit: a qualified small business, broadly one with gross receipts under $5 million and no gross receipts more than five years back, can elect to apply up to $500,000 of the credit each year against employer payroll taxes.

The One Big Beautiful Bill Act also restored immediate deduction of domestic research and experimental expenditures (new Section 174A) for tax years beginning after 31 December 2024, reversing the five-year amortization that applied from 2022. Eligible small businesses can elect to apply the change retroactively to earlier years.

Common mistakes

  • Assuming SBIR solicitations reopened everywhere at once after April 2026.
  • Missing the payroll offset election because the company has no income tax.
  • Not keeping contemporaneous records of research projects and time, which the credit requires.

For education only, not legal, tax or investment advice. Rules and terms change; check the primary sources and ask your lawyer or accountant before you act. How we write and review these pages.

Frequently asked questions

Is SBIR funding available again?

Yes. The programs were reauthorized on 13 April 2026 through 30 September 2031. Agencies have restarted solicitations at different speeds, so check each agency's SBIR page.

Can a startup with no profits use the R&D tax credit?

Yes. A qualified small business can elect to apply up to $500,000 a year of the credit against employer payroll taxes.

Does SBIR funding dilute founders?

No. SBIR and STTR awards are grants or contracts, not equity investments.

Sources

  1. Congressional Research Service: Small business research programs reauthorized after six-month lapse (IN12705)
  2. FASEB Washington Update: SBIR/STTR five-year reauthorization (about $4 billion a year)
  3. Crowell & Moring: SBIR/STTR programs reauthorized after six-month lapse
  4. NYSSCPA: R&D credits after OBBBA, including the payroll tax offset
  5. CLA: The R&D tax credit and deduction, filing changes
  6. 26 U.S. Code ยง 41, Credit for increasing research activities (Cornell LII)

Important information. This publication is provided for general information only and reflects the views of Cash Capital as of its date. It is not investment, legal, tax or accounting advice, and it is not an offer to sell, or a solicitation of an offer to buy, any security or any interest in any fund.

Figures, statistics and company information are drawn from third-party sources that we believe to be reliable, including news reports, data providers and company announcements. We have not independently verified them, and some may be estimates, preliminary, reported rather than confirmed, or later revised. Cash Capital makes no representation or warranty as to their accuracy, completeness or timeliness and accepts no liability for any loss arising from reliance on them. Readers should consult the original sources and their own advisers before making any decision.

Predictions, outlooks and other forward-looking statements are opinions about uncertain future events and may not occur. We do not undertake to update this publication. Companies named are used for illustration only; unless stated otherwise they are not Cash Capital portfolio companies, and naming them does not imply any relationship, endorsement or recommendation. See our Terms & Disclosures.

Building something consequential?

Send us your pitch. A partner reads every submission, and you will hear back from us either way.

Pitch Us ›